甘李药业发预增，预计2025年度归母净利润同比增加78.96%到95.23%

Core Viewpoint - Ganli Pharmaceutical (603087.SH) expects a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of the parent company between 1.1 billion to 1.2 billion yuan, representing a year-on-year increase of 78.96% to 95.23% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit increase of 485 million to 585 million yuan compared to the previous year [1] - The projected net profit growth is primarily driven by revenue growth in domestic and international markets, as well as gains from equity transfers [1] Group 2: Domestic Market Strategy - In the domestic market, the company has leveraged its market coverage advantage gained from centralized procurement, leading to significant growth in both sales volume and revenue of insulin preparations [1] Group 3: International Market Strategy - The company is actively advancing its internationalization strategy, achieving notable success in emerging markets along the "Belt and Road" initiative, resulting in increased sales and trust from international clients [1] Group 4: Equity Transfer - In 2025, the company reached an agreement to transfer 70% of the equity of its wholly-owned subsidiary, Gan Medical Technology Jiangsu Co., Ltd., to Guangdong Hengqin Ganling Enterprise Management Co., Ltd. in two phases [1] - The first phase of the transaction has been completed, with 55% of the equity successfully transferred, contributing to increased investment income and net profit [1]